United States Patent 9,107,898: Doxepin Sleep-Maintenance Insomnia Claims and Patent Landscape

U.S. Patent No. 9,107,898 protects a narrow method of using low-dose doxepin, generally 3 mg to 6 mg, to treat sleep-maintenance insomnia in elderly patients. The claims focus on fragmented sleep or early awakenings during the final 60 minutes of an intended eight-hour sleep period. The patent does not broadly cover doxepin, all insomnia treatment, or every use of 3 mg or 6 mg doxepin.

The principal infringement risks arise from a product or clinical protocol that combines four elements: an elderly patient, sleep-maintenance insomnia occurring during the eighth hour, bedtime administration of doxepin at 3 mg to 6 mg, and an intended reduction in late-night fragmentation or early awakening.[1]

What does U.S. Patent 9,107,898 protect?

U.S. Patent 9,107,898 is a method-of-treatment patent directed to low-dose doxepin therapy for a specific insomnia phenotype. Its independent claims are claims 1 and 6.

Claim	Protected method	Required clinical feature	Dose
1	Treating sleep-maintenance insomnia characterized by fragmented sleep	Fragmented sleep during the final 60 minutes of an intended eight-hour period	At least 3 mg and up to 6 mg
6	Treating sleep-maintenance insomnia characterized by early awakenings	Early awakenings during the final 60 minutes of an intended eight-hour period	At least 3 mg and up to 6 mg

Both independent claims require:

Identification of an elderly patient.
A sleep disorder involving the final 60 minutes of an eight-hour desired sleep period.
Administration before the sleep period.
Doxepin or a pharmaceutically acceptable salt.
A dose from 3 mg through 6 mg.
Improvement in sleep-maintenance insomnia through reduced late-night fragmentation or early awakenings.

The patent therefore protects a treatment protocol, not a chemical compound or a general pharmaceutical composition.

How broad are the claims of Patent 9,107,898?

The claims are commercially relevant but technically narrow. A competing product or treatment method must satisfy the limitations of an asserted claim. A doxepin product used outside the claimed patient population, dose range, timing, or sleep endpoint may avoid literal infringement.

Patient limitation: elderly patient

Claims 1 and 6 require an “elderly patient.” The claims supplied do not state a numerical age threshold. That creates a claim-construction issue. The specification, prosecution history, clinical protocol, and ordinary medical meaning would likely be relevant to determining whether a particular patient qualifies.

A product label that recommends treatment for adults generally may create a different infringement question from a protocol expressly targeting elderly patients. A generic manufacturer could also argue that its labeling does not direct physicians to select the claimed population.

Sleep-period limitation: the eighth hour

The claims require an intended eight-hour sleep period and focus on the final 60 minutes. This is narrower than a claim covering any sleep-maintenance insomnia.

The limitation creates several potential distinctions:

A patient who awakens during the fifth or sixth hour may not satisfy the literal eighth-hour limitation.
A protocol aimed at total sleep time without targeting the eighth hour may not expressly meet the claim.
A sleep period shorter or longer than eight hours may raise a noninfringement issue.
“Fragmented sleep” and “early awakenings” may require clinical interpretation and evidence.

The patent’s commercial relevance is strongest where prescribing materials, clinical studies, or physician instructions specifically address late-night awakening or sleep continuity during the final hour.

Dose limitation: 3 mg to 6 mg

The claimed range includes 3 mg, 6 mg, and intermediate doses. It excludes doses below 3 mg and above 6 mg under ordinary literal-claim analysis.

The range is important because low-dose doxepin products are associated with sleep-maintenance treatment, while higher-dose doxepin products historically have been used for psychiatric indications. A product containing 10 mg, 25 mg, or 50 mg doxepin would not literally meet the claimed dose limitation, although a doctrine-of-equivalents theory would require a separate analysis.

Timing limitation: before the sleep period

The drug must be administered before the sleep period. A bedtime instruction would generally be closer to the claim than an administration schedule during the night. A product directed to as-needed middle-of-the-night dosing could create a material noninfringement distinction.

What do the dependent claims add?

Claims 2, 3, 4, 5, 7, 8, 9, and 10 depend on claims 1 or 6.

Dependent claims	Added limitation
2 and 7	Improvement while minimizing next-day residual sedation
3 and 8	Chronic insomnia
4 and 9	Non-chronic insomnia
5 and 10	Transient insomnia

Claims 3 through 5 and 8 through 10 create alternative duration categories. They do not materially expand the independent claims because each remains subject to the elderly-patient, eighth-hour, timing, doxepin, and 3 mg-to-6 mg requirements.

Claims 2 and 7 are narrower than their parent claims. “Minimizing next-day residual sedation” may require evidence comparing the treated patient’s next-day sedation with a baseline, comparator, or clinically meaningful threshold. The phrase could create both an infringement evidentiary burden and an invalidity issue if the patent does not provide an objective standard.

What is the claim scope for Silenor and low-dose doxepin?

Silenor is an FDA-approved doxepin tablet product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.[2] The approved strengths are 3 mg and 6 mg. The dosage form and indication align closely with the numerical dose and sleep-maintenance limitations in Patent 9,107,898.

That overlap does not mean every sale or prescription of Silenor infringes. Patent infringement generally depends on the claimed method of use, including patient selection and the specific sleep endpoint. A manufacturer’s labeling, promotional activity, or induced prescribing may be relevant where the label directs the patented use.

The patent is more closely aligned with the pharmacologic and clinical positioning of low-dose doxepin than with conventional antidepressant-dose doxepin. Low-dose doxepin acts primarily as an antagonist at the histamine H1 receptor, while higher doses have broader pharmacologic activity.[2]

What patents protect low-dose doxepin insomnia treatment?

The low-dose doxepin estate has included multiple patent categories:

Patent category	Typical subject matter	Relevance to Patent 9,107,898
Method-of-use patents	Treatment of sleep-maintenance insomnia	Directly relevant
Formulation patents	Low-dose tablets, excipients, dissolution, stability, or dosage forms	Potentially separate product barrier
Clinical-use patents	Specific patient populations, sleep endpoints, or reduced residual sedation	Overlapping but narrower protection
Compound patents	Doxepin molecule or broad tricyclic chemistry	Generally historic and expired
Regulatory exclusivity	FDA new-drug or clinical exclusivity	Separate from patent rights

Patent 9,107,898 is not a formulation patent based on the supplied claims. It does not require a particular excipient, tablet architecture, release profile, particle size, manufacturing process, or impurity specification.

A generic tablet could therefore avoid this patent only if it also avoids any separately enforceable formulation or method-of-use rights. Conversely, a formulation that is chemically identical to the reference product could still face method-of-use exposure if its labeling directs the claimed treatment.

When does U.S. Patent 9,107,898 lose exclusivity?

Patent expiration cannot be calculated from the issue date alone. The relevant calculation requires the earliest effective nonprovisional filing date, patent-term adjustment, patent-term extension, terminal disclaimers, and any priority or continuation relationships.

The patent issued on August 18, 2015.[1] Its issue date does not establish the expiration date. A patent issued from a continuation application generally receives a term measured from the earliest effective nonprovisional filing in the relevant family, subject to statutory adjustments.

The FDA Orange Book, USPTO patent records, patent-family data, and any terminal-disclaimer information should be reviewed together before using an expiration date for a launch or valuation model.[3][4]

What is the Orange Book status of low-dose doxepin?

FDA Orange Book listings are product-specific. They identify patents submitted by the NDA holder for a listed drug and can include drug-substance, drug-product, and method-of-use patents.[3]

For low-dose doxepin, the relevant commercial product is Silenor, marketed in 3 mg and 6 mg tablet strengths. An Orange Book listing does not independently establish that every listed patent is valid or infringed. It creates a regulatory framework for an abbreviated new drug application that includes a Paragraph IV certification.

The principal Orange Book questions are:

Whether Patent 9,107,898 is listed against the relevant Silenor strengths.
Whether the listing is a method-of-use patent.
Whether the use code covers sleep-maintenance insomnia generally or a narrower approved use.
Whether other listed formulation patents remain active.
Whether any 30-month stay or pediatric-exclusivity period affects approval timing.

How do Paragraph IV challenges affect generic doxepin entry?

A generic applicant seeking approval for 3 mg or 6 mg doxepin tablets may use one of four principal patent certifications:

Certification	Meaning
Paragraph I	No patent information has been submitted
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Listed patent is invalid, unenforceable, or will not be infringed

A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. If the NDA holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.[5]

For Patent 9,107,898, a Paragraph IV challenge would likely focus on:

Whether the generic label induces use in elderly patients.
Whether the label directs treatment of eighth-hour awakenings.
Whether the claimed clinical endpoints are inherent in ordinary sleep-maintenance treatment.
Whether prior art disclosed low-dose doxepin for late-night sleep continuity.
Whether “elderly,” “fragmented sleep,” “early awakenings,” and “minimizing residual sedation” are definite and adequately supported.
Whether the asserted claims are obvious in view of doxepin pharmacology, earlier clinical studies, and FDA-approved sleep-maintenance uses.

A generic applicant may also pursue a “section viii” labeling carve-out for patented methods of use, where permitted. The viability of that strategy depends on the exact Orange Book use code and whether the remaining label still encourages the patented method.[3][5]

What invalidity arguments are most significant?

Obviousness

Obviousness is likely the central validity issue. Doxepin was known before the patent, and low-dose use for insomnia was disclosed in the clinical and patent literature. The key question would be whether the specific combination of elderly patients, eighth-hour sleep disruption, 3 mg-to-6 mg dosing, and reduced residual sedation was an obvious optimization or a non-obvious clinical discovery.[1]

Anticipation

Anticipation would require a single prior-art reference to disclose every limitation. Broad disclosure of doxepin for insomnia may not anticipate the specific eighth-hour endpoint unless the reference expressly or inherently teaches that feature.

Indefiniteness

Potentially ambiguous terms include:

“Elderly patient”
“Fragmented sleep”
“Early awakenings”
“Effective to improve”
“Minimizing next day residual sedation”
“For a given 8 hour period of desired sleep”

The strength of an indefiniteness challenge would depend on whether the specification and prosecution record provide objective boundaries.

Written description and enablement

The patent must support the claimed patient category, dose range, sleep-period limitation, and clinical outcomes across the full claim scope. Claims covering chronic, non-chronic, and transient insomnia may be tested against the breadth of the disclosed clinical evidence.

What formulation patents and manufacturing barriers remain?

Patent 9,107,898 does not claim manufacturing or formulation technology. A competing manufacturer must separately assess:

Tablet composition and excipient selection.
Dissolution and stability specifications.
Bioequivalence requirements.
Manufacturing controls for 3 mg and 6 mg strengths.
Proprietary analytical methods.
Trade-secret manufacturing processes.
FDA labeling and use-code restrictions.
Other active patents listed for the reference product.

The principal manufacturing barrier for low-dose doxepin is likely dose uniformity and product performance at very low drug loads rather than chemical synthesis. That issue may support formulation claims in a separate patent family, but it is not required by the claims supplied for Patent 9,107,898.

Which companies are challenging low-dose doxepin exclusivity?

The supplied patent claims do not identify a particular Paragraph IV filer, litigation docket, settlement agreement, or license. Those facts cannot be inferred from the claim language.

The relevant competitive groups are:

The branded low-dose doxepin sponsor and its commercial successor.
Generic pharmaceutical companies seeking approval for 3 mg and 6 mg tablets.
Manufacturers of higher-dose doxepin capsules or oral solutions.
Digital and behavioral insomnia-treatment providers that do not rely on doxepin.
Alternative sleep-maintenance products, including orexin antagonists and other sedative-hypnotics.

A generic version of an antidepressant-dose doxepin product is not automatically a substitute for an FDA-approved 3 mg or 6 mg sleep-maintenance tablet. Dosage strength, label, tablet design, and payer coverage affect the competitive relationship.

How strong is the patent estate for low-dose doxepin?

Patent 9,107,898 has moderate claim specificity and potentially meaningful label-based enforcement value. Its strengths are the close alignment with the 3 mg and 6 mg low-dose regimen and the sleep-maintenance indication. Its weaknesses are the number of clinical and definitional limitations and the potential for prior-art and obviousness challenges.

Factor	Assessment
Chemical coverage	None in the supplied claims
Formulation coverage	None in the supplied claims
Method-of-use coverage	Yes
Dose specificity	High
Patient specificity	High
Endpoint specificity	High
Label-based enforcement potential	Material if the label directs the claimed use
Design-around potential	Moderate
Obviousness exposure	Material
Manufacturing barrier	Not established by these claims

Key Takeaways

Patent 9,107,898 is a method-of-treatment patent for low-dose doxepin.
Claims 1 and 6 require an elderly patient, an intended eight-hour sleep period, and late-night sleep fragmentation or early awakening during the final 60 minutes.
The dose range is 3 mg through 6 mg, administered before the sleep period.
Claims 2 and 7 add minimization of next-day residual sedation.
Claims 3 through 5 and 8 through 10 address chronic, non-chronic, and transient insomnia.
The patent does not claim doxepin itself, a tablet formulation, or a manufacturing process.
A generic challenge would likely focus on obviousness, claim construction, induced infringement, and the availability of a section viii label carve-out.
Patent expiration must be determined from the patent family, effective filing date, patent-term adjustment, terminal disclaimers, and Orange Book data rather than the issue date alone.
The commercial risk is highest for a 3 mg or 6 mg doxepin label expressly targeting elderly patients with late-night sleep-maintenance problems.

FAQs About U.S. Patent 9,107,898

Does Patent 9,107,898 cover all doxepin products?

No. The supplied claims cover a specific method using 3 mg to 6 mg doxepin for elderly patients with defined late-night sleep-maintenance symptoms.

Does a 6 mg doxepin tablet necessarily infringe the patent?

No. Dose alone is insufficient. The patient population, sleep-period characteristics, timing, and claimed treatment outcome also matter.

Can a generic manufacturer sell doxepin for depression while Patent 9,107,898 remains active?

Potentially, subject to other patents and regulatory restrictions. Higher-dose antidepressant use may fall outside the claims, but induced-infringement and labeling issues require analysis of the complete product label.

Is Patent 9,107,898 a formulation patent?

No. The supplied claims do not require a particular formulation, excipient, release profile, tablet structure, or manufacturing process.

Does an FDA Orange Book listing prove that Patent 9,107,898 is valid?

No. An Orange Book listing supports the regulatory patent-certification process. It does not establish validity, enforceability, or infringement.

References

United States Patent and Trademark Office. (2015). U.S. Patent No. 9,107,898, methods of treating insomnia.
U.S. Food and Drug Administration. (2010). Silenor (doxepin) tablets prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (n.d.). Patent Center and patent term adjustment records.
21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-001	Mar 17, 2010	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2687118	⤷ Start Trial
Canada	2687124	⤷ Start Trial
European Patent Office	2026792	⤷ Start Trial
Japan	2009537553	⤷ Start Trial
Japan	2009537554	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,107,898

Which drugs does patent 9,107,898 protect, and when does it expire?

Summary for Patent: 9,107,898